NCT03508609View on ClinicalTrials.gov

Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

December 10, 2019

Study Completion Date

May 5, 2020

Conditions
Coronary Microvascular Dysfunction
Interventions
BIOLOGICAL

CLBS16

GCSF-mobilized autologous CD34 cells

Trial Locations (2)

55905

Mayo Clinic in Rochester, Rochester

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Cedars-Sinai Medical Center

OTHER

collaborator

Mayo Clinic

OTHER

lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT03508609 - Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease | Biotech Hunter | Biotech Hunter